SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
A statement from Hooters of America by Ericka Whitaker (Hooters of America senior brand manager) stated that she had no issue of having blonde highlights as a Hooters Girl prior to becoming a brand manager and the company will continue to diversify its employees, from the restaurant to the annual Hooters International Swimsuit Pageant. On September 11, 2017, former Philadelphia-area Hooters waitress Jade Velez filed a lawsuit against Hooters alleging she was a victim of workplace sexual assault by a former kitchen employee. The lawsuit named the employee, three former managers at the Northeast Philadelphia Hooters restaurant where she worked, and Hooters of America, LLC et al as defendants. As of July 2020, the outcome of the case was still pending. On July 16, 2019, Scott Peterson, who was one of two men who alleged they were sexually harassed by a male boss while working for Hooters in the Los Angeles area, reached a settlement with the restaurant chain in the Los Angeles Superior Court, though terms of the settlement were not publicly revealed. The other plaintiff, Paul "PJ" Cagnina, obtained a settlement in May 2017. On August 22, 2024, Hendrick Motorsports of NASCAR announced that they would sue Hooters for $1.705 million plus unpaid sponsorship fees. On March 21, 2025, it was reported that Hooters agreed to pay $900K to Hendrick Motorsports. On October 22, 2024, Hooters of America settled a claim from the Equal Employment Opportunity Commission that black employees were not recalled back to work after the COVID-19 pandemic at the same levels as white employees.
Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met (RPKPQQFFGLM) with an amide group at the C-terminus. Substance P is released from the terminals of specific sensory nerves. It is found in the brain and spinal cord and is associated with inflammatory processes and pain.
==== Types of drug controls ==== There are two different types of controls that can be conducted in competition or in training. It is important that tests are conducted by independent organizations that treat each athlete equally, indifferent of fame or nationality.
Sources: en.wikipedia.org
Recently, an efficient stepwise solid-phase synthesis of RANTES (24-91) was published. RANTES is a major HIV-suppressive factor produced by CD8+ T Cells. The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) induces a NH2-terminal truncation from RANTES (1-91) to RANTES(24-91), which inhibits the infection of monocytes by an M-tropic HIV-1 strain The 68 amino acid of RANTES(24-91) has a high propensity to aggregate. The method combines the advantages of the PEG-based ChemMatrix resin and pseudoproline dipeptides. Direct coupling to pseudoproline monomer. Senko and his colleagues were the first to confirm the effectiveness of pseudoproline derivatives of individual, single residues in polypeptide synthesis. According to literature, the conversion of Ser(ΨPro) was excellent, however the Thr(ΨPro) varied in a wide range. The acylation of Pseudoproline monomer depended also on the chemical nature of the acylating residue. Manne and his colleagues successfully synthesized a human Growth Hormone (hGH)-derived polypeptide that was previously challenging to access, using Ser(ΨPro), while JR10 utilized Thr(ΨPro). Building upon Senko et al.'s work, Szaniszló and co-workers have recently improved the acylating efficiency of Thr(ΨPro) and incorporated it into their continuous flow peptide synthesizer.
Distal stabilisation of muscles is often performed. This allows effective muscle contraction which reduces atrophy, allows functional use of the stump and maintains soft tissue coverage of the remnant bone. The preferred stabilisation technique is myodesis where the muscle is attached to the bone or its periosteum. In joint disarticulation amputations tenodesis may be used where the muscle tendon is attached to the bone. Muscles are attached under similar tension to normal physiological conditions. An experimental technique known as the "Ewing amputation" aims to improve post-amputation proprioception. Another technique with similar goals, which has been tested in a clinical trial, is Agonist-antagonist Myoneural Interface (AMI). In 1920, Dr. Janos Ertl Sr. of Hungary, developed the Ertl procedure in order to return a high number of amputees to the workforce. The Ertl technique, an osteomyoplastic procedure for transtibial amputation, can be used to create a highly functional residual limb. Creation of a tibiofibular bone bridge provides a stable, broad tibiofibular articulation that may be capable of some distal weight bearing. Several different modified techniques and fibular bridge fixation methods have been used; however, no current evidence exists regarding comparison of the different techniques.
In Japan, iced coffee (アイスコーヒー, aisu kōhī) has been drunk since the Taishō period (around the 1920s) in coffeehouses. It is served with gum syrup and milk. Cold tea was already popular, so it was natural to drink cold coffee. Cold brew coffee is also common in Japan, where it is known as Dutch coffee (ダッチ・コーヒー, dacchi kōhī), due to the historical Dutch coffee trade from Indonesia. In 1969, UCC Ueshima Coffee released canned coffee, which made coffee available everywhere. Today, canned liquid coffee is consumed both cold and hot. Some Japanese iced coffee is prepared by brewing the coffee with hot water and allowing the coffee to drip over ice cubes. The volume of hot water is reduced to account for the dilution of the coffee by the melting ice. This method produces results similar to other iced coffees but is comparable to brewing hot coffee in time and effort.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.